The company announced a reorganization that included layoffs.
The company is facing being delisted from the S&P 600 Index.
An interim analysis for the company's Huntington's disease gene therapy wasn't a hit with investors.
Investors are focusing on the negative parts of the biotech company's interim results.
The S&P 500 Index ( $SPX ) ( SPY ) is up +0.09%, the Dow Jones Industrials Index ( $DOWI ) ( DIA ) is up +0.01%, and the Nasdaq 100 Index ( $IUXX ) ( QQQ ) is up +0.35%. U.S. stock index futures this morning...
uniQure (QURE) delivered earnings and revenue surprises of -59.80% and 79.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Investors need to pay close attention to UniQure (QURE) stock based on the movements in the options market lately.